Ibogaine Clinical Trials 2026

DemeRx Inc. holds the most strategically significant position in ibogaine's regulatory future. As the holder of the first FDA Investigational New Drug (IND) application for an ibogaine-class compound, DemeRx has cleared the primary regulatory hurdle required to conduct human trials with a path toward approval in the United States.

Their compound — an ibogaine derivative designed to preserve the anti-addictive mechanism while reducing the cardiac QTc prolongation associated with the parent molecule — is undergoing Phase II/III evaluation at multiple US sites for opioid use disorder (OUD). The multi-site design accelerates enrollment and builds the statistical power FDA requires for efficacy submissions.

Key investigators include neuropsychopharmacologists with backgrounds in NIDA-funded addiction research. The trial timeline targets Phase III completion by 2028, with an NDA submission possible in 2029-2030 if Phase II results support advancement. A successful DemeRx outcome would not just bring one drug to market — it would open the regulatory door for the entire ibogaine class.

The Stanford MISTIC (Mechanisms of Ibogaine's Sustained Treatment in Cocaine and opioid disorders) trial represents a watershed moment in American academic medicine's engagement with ibogaine. Stanford's involvement signals a shift from ibogaine being studied primarily in observational or overseas settings to receiving rigorous randomized controlled trial scrutiny at a tier-one US research university.

The trial focuses on ibogaine's efficacy in opioid use disorder, with a secondary aim of elucidating the neurobiological mechanisms underlying its sustained effects — addressing the critical gap between observed clinical outcomes and understood pharmacology. This mechanistic component will generate publishable data that informs every subsequent trial in the field.

Recruiting patients are screened for cardiac safety using the protocol developed from the MAPS/NIDA ibogaine safety literature. Stanford's involvement means MISTIC data will carry institutional credibility with the FDA reviewers, journal editors, and institutional review boards who will shape ibogaine's regulatory trajectory over the next decade.

The Texas Legislature's $50 million allocation to the UTHealth/UTMB ibogaine research program is the largest single government investment in ibogaine science in any jurisdiction globally. Passed in 2023 and operationalized in 2024, the IMPACT (Ibogaine for Mental and Physical Health After Combat Trauma) program was initially shaped around veteran populations — the population whose ibogaine data, from both uncontrolled naturalistic studies and the Stanford veteran trial published in Nature Medicine, most compellingly demonstrates efficacy.

The scope of the UTHealth investment extends well beyond veteran PTSD. Active substudies cover opioid use disorder, traumatic brain injury (TBI), treatment-resistant depression, and Parkinson's disease — conditions where ibogaine's GDNF-upregulating and neuroplasticity-promoting mechanisms offer theoretical benefit. Each substudy generates independent publishable data while contributing to the comprehensive safety profile regulators require.

UTMB's Galveston campus provides the biocontainment-level biosafety infrastructure and intensive care capacity needed for the highest-acuity cardiac monitoring protocols. The multi-institutional structure allows sample sizes that no single-site academic trial could achieve in a comparable timeframe, making the Texas program the most powerful generator of ibogaine clinical evidence currently operating.

ICEERS — the Barcelona-based research organization with two decades of expertise in ethnobotanical medicine policy and harm reduction science — has positioned itself as the European counterpart to American academic ibogaine research. Their regulatory-compliant trial structure, developed in partnership with Spanish and Dutch regulatory bodies, represents the first European Medicines Agency (EMA)-adjacent ibogaine trial framework.

The ICEERS trial design is notable for its breadth: unlike most ibogaine trials that target a single substance use disorder, the ICEERS protocol covers opioid, alcohol, and stimulant use disorders within a unified clinical framework. This broadens the evidentiary base for potential EMA review while generating comparative data on ibogaine's efficacy across substance classes.

ICEERS's existing relationships with harm reduction networks across Portugal (where personal drug possession is decriminalized), the Netherlands, and Spain provide access to patient populations unreachable through traditional addiction medicine pathways. The resulting dataset will likely be the most pharmacologically and demographically diverse ibogaine trial dataset assembled to date.

The University of Kentucky's neuropharmacology laboratory has produced some of the most cited foundational research in the ibogaine field — particularly the GDNF upregulation findings that explain why ibogaine's anti-addictive effects persist long after the acute experience. Active research continues to map ibogaine's multi-receptor pharmacology with precision that clinical trials require for mechanistic hypothesis testing.

Current work focuses on differentiating ibogaine's interactions at mu-opioid receptors (acute agonism followed by prolonged reset), NMDA receptors (antagonism shared with ketamine, providing rapid antidepressant activity), serotonin transporters (SERT inhibition distinct from SSRIs), and sigma-2 receptors (implicated in cellular stress pathways and potentially cancer biology). Each receptor system represents a potential independent therapeutic mechanism.

The translational bridge between Kentucky's bench science and clinical trial design is direct: the MISTIC trial and DemeRx Phase II pharmacodynamic endpoints are built on Kentucky's receptor binding data. Understanding which receptor interaction produces which clinical outcome allows trial designers to select biomarkers, design dose-escalation protocols, and interpret results with mechanistic confidence absent from early ibogaine research.

Johns Hopkins' Center for Psychedelic and Consciousness Research — the world's first academic psychedelic research center — has built the institutional infrastructure, IRB protocols, and clinical expertise that every serious psychedelic trial draws on. While Hopkins' primary published work has focused on psilocybin for smoking cessation, depression, and alcohol use disorder, ibogaine research is an active area within the center's expanding portfolio.

The Hopkins team's contribution to ibogaine science is methodological as much as empirical: their set-and-setting protocols, integration therapy frameworks, and safety monitoring standards have become de facto industry benchmarks. Any ibogaine clinical trial seeking FDA engagement will face comparison to Hopkins' psilocybin trial methodology — a standard that has produced reproducible, peer-reviewed data in high-impact journals including Nature Medicine and NEJM.

Hopkins' involvement in ibogaine-adjacent research also serves a signaling function for the broader scientific community. When researchers of Roland Griffiths and Matthew Johnson's caliber engage with a compound class, the implicit message to IRBs, funders, and regulators is that serious science — not fringe advocacy — is driving the inquiry. This reputational effect accelerates ibogaine's transition from Schedule I stigma to legitimate clinical candidate.

Cardiac health

Normal QTc on 12-lead EKG. No arrhythmia, structural heart disease, or history of sudden cardiac arrest.

Medication-free window

Most trials require 2-4 week washout from SSRIs, antipsychotics, and opioid maintenance medications.

Confirmed substance use disorder

Active or recent OUD, alcohol use disorder, or stimulant use disorder — depending on trial focus.

Age 18-65

Most trials enroll adults 18-65. Some veteran-focused trials extend to 70.

Psychiatric stability

No active psychosis, mania, or suicide attempt within 12 months. Stable depression/anxiety often acceptable.

Location access

Current trials are primarily US and European sites. Travel to site required.